Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2007 1
2009 3
2010 1
2011 2
2012 4
2013 4
2014 4
2015 3
2016 1
2017 4
2018 3
2019 6
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed for Bookshelf ID: 4866088

38 results

Results by year

Filters applied: . Clear all
Page 1
4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
Velayutham B, Jawahar MS, Nair D, Navaneethapandian P, Ponnuraja C, Chandrasekaran K, Narayan Sivaramakrishnan G, Makesh Kumar M, Paul Kumaran P, Ramesh Kumar S, Baskaran D, Bella Devaleenal D, Sirasanambati DR, Vasantha M, Palaniyandi P, Ramachandran G, Uma Devi KR, Elizabeth Hannah L, Sekar G, Radhakrishnan A, Kalaiselvi D, Dhanalakshmi A, Thiruvalluvan E, Raja Sakthivel M, Mahilmaran A, Sridhar R, Jayabal L, Rathinam P, Angamuthu P, Soorappa Ponnusamy K, Venkatesan P, Natrajan M, Prasad Tripathy S, Swaminathan S. Velayutham B, et al. Trop Med Int Health. 2020 Apr;25(4):483-495. doi: 10.1111/tmi.13371. Epub 2020 Feb 3. Trop Med Int Health. 2020. PMID: 31944502 Free article. Clinical Trial.
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, Conradie F, Diacon AH, Ntinginya NE, Everitt DE, Haraka F, Li M, van Niekerk CH, Okwera A, Rassool MS, Reither K, Sebe MA, Staples S, Variava E, Spigelman M. Tweed CD, et al. Lancet Respir Med. 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12. Lancet Respir Med. 2019. PMID: 31732485 Free PMC article. Clinical Trial.
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID; STREAM Study Collaborators. Nunn AJ, et al. N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13. N Engl J Med. 2019. PMID: 30865791 Free article. Clinical Trial.
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB. File TM, et al. Clin Infect Dis. 2019 Nov 13;69(11):1856-1867. doi: 10.1093/cid/ciz090. Clin Infect Dis. 2019. PMID: 30722059 Free PMC article. Clinical Trial.
Safety and Tolerability of Moxifloxacin in Children.
Dixit A, Karandikar MV, Jones S, Nakamura MM. Dixit A, et al. J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):e92-e101. doi: 10.1093/jpids/piy056. J Pediatric Infect Dis Soc. 2018. PMID: 29939314
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH. Tweed CD, et al. BMC Med. 2018 Mar 28;16(1):46. doi: 10.1186/s12916-018-1033-7. BMC Med. 2018. PMID: 29592805 Free PMC article.
38 results